Use of acyclovir in herpetic ocular infection.
Acyclovir has veen shown to have potent antiviral activity against both herpes simplex and herpes zoster viruses, especially the former, with low cellular toxicity, preferentially affecting virally infective cells by inhibiting viral DNA synthesis [1,2]. In experimental herpes simplex corneal infection, acyclovir has been found to be effective [3,4] and in early clinical trials it has been found to be at least as good as idoxuridine [5-7]. Acyclovir has also been found to have antiviral activity against the herpes zoster virus in tissue culture [1] and to affect favorably the course of the disease in immunosuppressed patients [8]. This paper describes the use of acyclovir in patients with either herpes simplex or herpes zoster ocular infections. Topical acyclovir has been compared with adenine arabinoside in the treatment of herpes simplex corneal ulceration in a coded clinical trial. The use of acyclovir will also be described in patients with complicated herpes simplex eye disease. Our initial results with topical acyclovir in herpes zoster keratouveitis are also described.
D000212:Acyclovir; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006147:Guanine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006562:Herpes Zoster / Q000188:drug therapy*; D006801:Humans; D007635:Keratitis, Dendritic / Q000188:drug therapy*; D008297:Male; D013256:Steroids / Q000627:therapeutic use; D014605:Uveitis / Q000188:drug therapy*
D000998:Antiviral Agents; D013256:Steroids; D006147:Guanine; D000212:Acyclovir